Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future

키워드

참고문헌 (75)

1. Wu W, "Worldwide longterm trends in the incidence of nonalcoholic fatty liver disease during 1990-2019 : a joinpoint and age-period-cohort analysis", Front Cardiovasc Med, 9, pp.891963~ (2022)
2. Younossi ZM, "Global epidemiology of nonalcoholic fatty liver disease-metaanalytic assessment of prevalence, incidence, and outcomes", Hepatology, 64, pp.73~84 (2016)
3. Kleiner DE, "Design and validation of a histological scoring system for nonalcoholic fatty liver disease", Hepatology, 41, pp.1313~1321 (2005)
4. Thoma C, "Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults : a systematic review", J Hepatol, 56, pp.255~266 (2012)
5. Katsagoni CN, "Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease : a meta-analysis", Metabolism, 68, pp.119~132 (2017)
6. Romero-Gómez M, "Treatment of NAFLD with diet, physical activity and exercise", J Hepatol, 67, pp.829~846 (2017)
7. Kuei-Chuan Lee, "Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis", Clinical and Molecular Hepatology, 29(1), pp.77~98 (2023), 대한간학회
8. Newsome PN, "Guidelines on the management of abnormal liver blood tests", Gut, 67, pp.6~19 (2018)
9. Gheorghe G, "The non-invasive assessment of hepatic fibrosis", J Formos Med Assoc, 120, pp.794~803 (2021)
10. Riazi K, "The prevalence and incidence of NAFLD worldwide : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 7, pp.851~861 (2022)
11. Gaidos JK, "A decision analysis study of the value of a liver biopsy in nonalcoholic steatohepatitis", Liver Int, 28, pp.650~658 (2008)
12. Rosenberg WM, "Serum markers detect the presence of liver fibrosis : a cohort study", Gastroenterology, 127, pp.1704~1713 (2004)
13. Vallet-Pichard A, "FIB-4 : an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest", Hepatology, 46, pp.32~36 (2007)
14. Angulo P, "The NAFLD fibrosis score : a noninvasive system that identifies liver fibrosis in patients with NAFLD", Hepatology, 45, pp.846~854 (2007)
15. Wai CT, "A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C", Hepatology, 38, pp.518~526 (2003)
16. Poynard T, "Overview of the diagnostic value of biochemical markers of liver fibrosis(FibroTest, HCV FibroSure)and necrosis(ActiTest)in patients with chronic hepatitis C", Comp Hepatol, 3, pp.8~ (2004)
17. Anstee QM, "Noninvasive tests accurately identify advanced fibrosis due to NASH : baseline data from the STELLAR trials", Hepatology, 70, pp.1521~1530 (2019)
18. Petta S, "Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD", Aliment Pharmacol Ther, 46, pp.617~627 (2017)
19. "How should I assess a person with NAFLD 2021"[URL]
20. "Nonalcoholic fatty liver disease (NAFLD): assessment and management"[URL]
21. 강성희, "KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 27(3), pp.363~401 (2021), 대한간학회
22. Byrne CD, "Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications", Diabetes Obes Metab, 24(Suppl 2), pp.28~43 (2022)
23. Mantovani A, "Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease : a systematic review", Lancet Gastroenterol Hepatol, 7, pp.367~378 (2022)
24. Reinson T, "Transient elastography in patients at risk of liver fibrosis in primary care : a follow-up study over 54 months", BJGP Open, 5, pp.BJGPO.2021~ (2021)
25. Asbaghi O, "Effects of the Mediterranean diet on cardiovascular risk factors in non-alcoholic fatty liver disease patients : a systematic review and meta-analysis", Clin Nutr ESPEN, 37, pp.148~156 (2020)
26. Baker CJ, "Effect of exercise on hepatic steatosis : are benefits seen without dietary intervention? a systematic review and metaanalysis", J Diabetes, 13, pp.63~77 (2021)
27. Younossi ZM, "Obeticholic acid for the treatment of nonalcoholic steatohepatitis : interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial", Lancet, 394, pp.2184~2196 (2019)
28. Rezaei S, "GLP-1 receptor agonist effects on lipid and liver profiles in patients with nonalcoholic fatty liver disease : systematic review and meta-analysis", Can J Gastroenterol Hepatol, 2021, pp.8936865~ (2021)
29. Gwyneth Soon, "Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective", Clinical and Molecular Hepatology, 27(1), pp.44~57 (2021), 대한간학회[DOI]
30. Reinson T, "Performance of the enhanced liver fibrosis (ELF)score, comparison with vibration-controlled transient elastography (VCTE) data, and development of a simple algorithm to predict significant liver fibrosis in a community-based liver service: a retrospective evaluation", Journal of Clinical and Translational Hepatology (2023)
31. Sterling RK, "Development of a simple noninvasive index to predict significant fibrosis in patients with HIV", HCV coinfection, 2006, pp.43, 1317~1325
32. Xiao G, "Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease : a meta-analysis", Hepatology, 66, pp.1486~1501 (2017)
33. Vali Y, "FibroTest for evaluating fibrosis in non-alcoholic fatty liver disease patients : a systematic review and meta-analysis", J Clin Med, 10, pp.2415~ (2021)
34. "Likelihood ratios & area under the curve"[URL]
35. Vali Y, "Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD : a systematic review and metaanalysis", J Hepatol, 73, pp.252~262 (2020)
36. Mak AL, "Systematic review with meta-analysis : diagnostic accuracy of Pro-C3 for hepatic fibrosis in patients with non-alcoholic fatty liver disease", Biomedicines, 9, pp.1920~ (2021)
37. Sripongpun P, "The steatosis-associated fibrosis estimator(SAFE)score : a tool to detect low-risk NAFLD in primary care", Hepatology (2022)[DOI]
38. Blanes-Vidal V, "Artificial intelligence outperforms standard blood-based scores in identifying liver fibrosis patients in primary care", Sci Rep, 12, pp.2914~ (2022)
39. Carteri RB, "Machine learning approaches using blood biomarkers in non-alcoholic fatty liver diseases", Artif Intell Gastroenterol, 3, pp.80~87 (2022)
40. Wong GL, "Artificial intelligence in prediction of non-alcoholic fatty liver disease and fibrosis", J Gastroenterol Hepatol, 36, pp.543~550 (2021)
41. Angulo P, "Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease", Gastroenterology, 149, pp.389~397 (2015)
42. Taylor RS, "Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease : a systematic review and meta-analysis", Gastroenterology, 158, pp.1611~1625 (2020)
43. Peleg N, "Noninvasive scoring systems predict hepatic and extra-hepatic cancers in patients with nonalcoholic fatty liver disease", PLoS One, 13, pp.e0202393~ (2018)
44. Ito T, "Utility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsy-proven Japanese non-alcoholic fatty liver disease patients", J Gastroenterol Hepatol, 34, pp.207~214 (2019)
45. Lee J, "Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events : a systematic review", Liver Int, 41, pp.261~270 (2021)
46. Cianci N, "Prognostic non-invasive biomarkers for all-cause mortality in non-alcoholic fatty liver disease : a systematic review and metaanalysis", World J Hepatol, 14, pp.1025~1037 (2022)
47. Allen AM, "Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design", J Hepatol, 77, pp.1237~1245 (2022)
48. Parkes J, "Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease", Gut, 59, pp.1245~1251 (2010)
49. "FDA grants marketing authorization to siemens healthineers ELF test for NASH prognostic assessment"[URL]
50. "The ELF test as a universally available prognostic tool for enhancing NASH patient care"[URL]
51. Hagström H, "Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease", J Hepatol, 73, pp.1023~1029 (2020)
52. Balkhed W, "Repeated measurements of non-invasive fibrosis tests to monitor the progression of non-alcoholic fatty liver disease : a long-term follow-up study", Liver Int, 42, pp.1545~1556 (2022)
53. Hwi Young Kim, "Recent advances in nonalcoholic fatty liver disease metabolomics", Clinical and Molecular Hepatology, 27(4), pp.553~559 (2021), 대한간학회[DOI]
54. Gang Xu, "Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis", Clinical and Molecular Hepatology, 27(2), pp.329~345 (2021), 대한간학회[DOI]
55. Ampuero J, "Systematic review and meta-analysis : analysis of variables influencing the interpretation of clinical trial results in NAFLD", J Gastroenterol, 57, pp.357~371 (2022)
56. Harrison SA, "A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis", J Hepatol, 72, pp.816~827 (2020)
57. Neuschwander-Tetri BA, "Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis(FLINT) : a multicentre, randomised, placebocontrolled trial", Lancet, 385, pp.956~965 (2015)
58. Sanyal AJ, "Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis", N Engl J Med, 362, pp.1675~1685 (2010)
59. Cusi K, "Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus : a randomized trial", Ann Intern Med, 165, pp.305~315 (2016)
60. Ratziu V, "One-year results of the global phase 2b randomized placebo-controlled ARREST trial of aramchol, a stearoyl CoA desaturasemodulator in NASH patients", The Liver Meeting 2018 (2018)
61. Harrison SA, "RESOLVE-IT phase 3 of elafibranor in NASH : final results of the week 72 interim surrogate efficacy analysis", The Liver Meeting Digital Experience 2020 (2020)
62. Harrison SA, "A 52-week multi-center double-blind randomized phase 2 study of seladelpar, a potent and selective peroxisome proliferator-activated receptor delta (PPAR-delta) agonist, in patients with nonalcoholic steatohepatitis (NASH)", The Liver Meeting Digital Experience 2020 (2020)
63. Newsome PN, "A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis", N Engl J Med, 384, pp.1113~1124 (2021)
64. Friedman SL, "A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis", Hepatology, 67, pp.1754~1767 (2018)
65. Francque SM, "A randomized, controlled trial of the Pan-PPAR agonist lanifibranor in NASH", N Engl J Med, 385, pp.1547~1558 (2021)
66. Harrison SA, "Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis : a randomized, double-blind, placebo-controlled phase IIb study", J Hepatol, 72, pp.613~626 (2020)
67. Armstrong MJ, "Liraglutide safety and efficacy in patients with nonalcoholic steatohepatitis(LEAN) : a multicentre, doubleblind, randomised, placebo-controlled phase 2 study", Lancet, 387, pp.679~690 (2016)
68. Harrison SA, "Efficacy and safety of aldafermin, an engineered FGF19analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis", Gastroenterology, 160, pp.219~231 (2021)
69. Harrison SA, "Efruxifermin in non-alcoholic steatohepatitis : a randomized, double-blind, placebo-controlled, phase 2a trial", Nat Med, 27, pp.1262~1271 (2021)
70. Harrison SA, "Resmetirom(MGL-3196)for the treatment of non-alcoholic steatohepatitis : a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial", Lancet, 394, pp.2012~2024 (2019)
71. Ratziu V, "Elafibranor, an agonist of the peroxisome proliferatoractivated receptor-α and-δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening", Gastroenterology, 150, pp.1147~1159 (2016)
72. Chalasani N, "Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension", Gastroenterology, 158, pp.1334~1345 (2020)
73. Loomba R, "Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH", Hepatology, 73, pp.625~643 (2021)
74. Harrison SA, "Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH : results from randomized phase III STELLAR trials", J Hepatol, 73, pp.26~39 (2020)
75. Loomba R, "The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis : a randomized, phase 2 trial", Hepatology, 67, pp.549~559 (2018)

관련 논문AI추천